Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

NCT02258607 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

Interventions

DRUG: Momelotinib (MMB)
DRUG: Trametinib

Sponsor

Sierra Oncology LLC - a GSK company